Best Value Stocks to Buy for Jan.14

Zacks highlights three Zacks Rank #1 buy candidates with improving earnings estimates and attractive valuation metrics: Guess (GES) has a 5.6% upward revision to current-year estimates, a trailing P/E of 9.93 versus an industry 24.40 and a Value Score of B; National Energy Services Reunited (NESR) saw next-year estimates rise 4.1%, a trailing P/E of 11.85 versus industry 21.60 and Value Score A; Alkermes (ALKS) had a 3.1% increase in current-year estimates, a trailing P/E of 19.23 versus the S&P 25.72 and Value Score A. The note is a sector-diversified, value-oriented screen emphasizing upgraded analyst expectations and below-industry P/Es that may attract value-oriented and retail investors.

Analysis

Market structure: The three names (GES, NESR, ALKS) benefit from divergent sector drivers — cyclical consumer stabilization (GES), upstream capex rebound (NESR) and idiosyncratic biotech re-rating (ALKS). NESR is the clearest direct beneficiary if Brent holds >$75/bbl (raises service utilization and dayrates); losers include smaller, highly leveraged service contractors and lower-margin fast-fashion peers who cannot regain pricing. Cross-asset: a sustained oil rally would lift NESR equity and widen commoditized capex flows, tighten high-yield spreads for strong service names and push USD strength that can compress EM-revenue margins.

Risk assessment: Key tail risks are an oil-price collapse to <$60 within 6 months (kills NESR demand), an adverse regulatory or trial outcome for ALKS (12-month binary), and a consumer-spend shock reducing GES comps by >3% QoQ. Time horizons: near-term (0–3 months) sensitivity to earnings/estimate revisions; medium (3–12 months) for re-rating on margin expansion or oil rig counts; long (12–36 months) for structural pipeline or brand repositioning. Hidden dependencies include FX exposure for NESR in MENA, inventory aging for GES, and payer/pricing negotiations for ALKS.

Trade implications: Tactical longs: size NESR 2–3% portfolio weight (target +30% in 6–12 months if EPS revisions continue; hard stop -18%); GES 1–2% for a +20–25% rerate if gross margins expand 150–300 bps over next two quarters; ALKS 1–1.5% as a catalyst-driven play (target +35% in 12 months, stop -20%). Pair ideas: long NESR vs short OIH (ETF) to capture company-specific execution; options: buy 6–9 month call spreads on NESR sized to 1% notional and protective puts on ALKS sized to 0.5–1% ahead of regulatory windows.

Contrarian angles: Consensus highlights value but may underweight execution/regulatory risk — ALKS’s mid‑teens P/E still prices clinical binary risk; GES’s low P/E gap (9.9 vs industry 24) could persist if inventory or credit trends reverse. Historical parallel: energy-service rebounds can take 12–18 months to manifest in revenue and margins, so short-term optimism may be premature. Unintended consequence: an oil-driven inflation spike could lift NESR revenue but increase rates and pressure consumer discretionary multiples, compressing GES unless sales resilient.

Key Decisions for Investors

• Establish a 2–3% long position in NESR (ticker NESR) within 2 weeks, target +30% over 6–12 months if Brent >$75 persists and EPS revisions continue; place a stop-loss at -18% to limit drawdown.
• Initiate a 1–2% long in GES (ticker GES) on signs of two consecutive quarterly gross margin improvements (≥150 bps combined QoQ); target +20–25% in 3–6 months, stop-loss -15% if same-store sales decline >3% QoQ.
• Add a 1–1.5% event-driven position in ALKS (ticker ALKS) with a 12-month horizon; hedge binary regulatory/trial risk by buying 9–12 month protective puts sizing total downside risk to 20% of position value; target +30–35% on positive catalysts or continued estimate upgrades.
• Execute a pair trade: go long NESR (2% portfolio) and short OIH (1.5% portfolio) to capture company-specific outperformance; monitor monthly rig-counts and relative EPS revisions, rebalance if divergence narrows to <3% performance gap over 60 days.
• Use options for asymmetric exposure: buy a 6–9 month NESR call spread sized to 1% notional (limits premium outlay while capturing upside >20%) and buy 3–6 month ALKS puts sized to 0.5–1% ahead of any regulatory/timeline catalysts.